Početna stranicaME • NASDAQ
add
23andMe Holding Co.
3,11 $
Poslije radnog vremena:(3,54 %)+0,11
3,22 $
Zatvoreno: 22. stu, 18:26:25 GMT -5 · USD · NASDAQ · Odricanje od odgovornosti
Preth. zaklj. cijena
3,23 $
Dnevni raspon
2,99 $ - 3,21 $
Godišnji raspon
2,66 $ - 20,20 $
Tržišna kapitalizacija
74,94 mil. USD
Prosječna količina
404,88 tis.
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
NASDAQ
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (USD) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Prihod | 44,07 mil. | −11,86 % |
Operativni troškovi | 81,33 mil. | −17,18 % |
Neto dohodak | −59,10 mil. | 21,48 % |
Neto profitabilnost | −134,11 | 10,91 % |
Zarada po dionici | — | — |
EBITDA | −54,96 mil. | 21,06 % |
Efektivna porezna stopa | 0,07 % | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (USD) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 126,60 mil. | −50,62 % |
Ukupna imovina | 318,94 mil. | −60,19 % |
Ukupne obveze | 217,01 mil. | 23,31 % |
Ukupni kapital | 101,93 mil. | — |
Dionice u optjecaju | 26,12 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 0,82 | — |
Povrat imovine | −42,89 % | — |
Povrat kapitala | −75,30 % | — |
Tok novca
Neto promjena novca
| (USD) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Neto dohodak | −59,10 mil. | 21,48 % |
Gotovina od poslovanja | −40,93 mil. | 28,34 % |
Gotovina iz ulaganja | −2,70 mil. | 2,63 % |
Gotovina iz financiranja | 260,00 tis. | −83,68 % |
Neto promjena novca | −43,37 mil. | 25,18 % |
Slobodan tok novca | −12,82 mil. | 59,90 % |
Više
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California. It is best known for providing a direct-to-consumer genetic testing service in which customers provide a saliva sample that is laboratory analysed, using single nucleotide polymorphism genotyping, to generate reports relating to the customer's ancestry and genetic predispositions to health-related topics. The company's name is derived from the 23 pairs of chromosomes in a diploid human cell.
Founded in 2006, 23andMe soon became the first company to begin offering autosomal DNA testing for ancestry, which all other major companies now use. Its saliva-based direct-to-consumer genetic testing business was named "Invention of the Year" by Time in 2008.
The company had a previously fraught relationship with the United States Food and Drug Administration due to its genetic health tests; as of October 2015, DNA tests ordered in the US include a revised health component, per FDA approval. 23andMe has been selling a product with both ancestry and health-related components in Canada since October 2014, and in the UK since December 2014. Wikipedia
Glavni izvršni direktor
Osnovano
tra 2006
Web-lokacija
Zaposlenici
571
